Thrombocytopenic Purpura, Autoimmune disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

AITP MCID: THR100 MIFTS: 59	Thrombocytopenic Purpura, Autoimmune (AITP) Categories: Blood diseases, Bone diseases, Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Thrombocytopenic Purpura, Autoimmune

MalaCards integrated aliases for Thrombocytopenic Purpura, Autoimmune:

Name: Thrombocytopenic Purpura, Autoimmune ⁵⁷ ⁷⁵ ¹²

Idiopathic Thrombocytopenic Purpura ⁵⁷ ¹¹ ¹⁹ ⁷⁵ ⁵ ¹⁴ ³⁸ ³¹ ³³

Autoimmune Thrombocytopenic Purpura ¹¹ ¹⁹ ²⁸ ⁵ ¹⁴ ¹⁶ ³³

Immune Thrombocytopenic Purpura ⁵⁷ ¹¹ ⁷¹ ⁷⁵ ³³

Idiopathic Purpura ¹¹ ³³

Itp ⁵⁷ ¹⁹

Thrombocytopenia Due to Platelet Alloimmunization ⁷¹

Itp - [idiopathic Thrombocytopenia Purpura] ³³

Primary Autoimmune Thrombocytopenic Purpura ³³

Purpura, Thrombocytopenic, Idiopathic ⁴³

Thrombocytopenic Purpura Autoimmune ¹⁹

Purpura Thrombocytopenic Idiopathic ⁵³

Idiopathic Thrombocytopenia Purpura ³³

Frank's Essential Thrombocytopenia ³³

Primary Thrombocytopenic Purpura ¹¹

Ideopath Thrombocytopenic Pur ¹¹

Autoimmune Thrombocytopenia ⁷¹

Idiopathic Thrombocytopenia ³³

Essential Thrombocytopenia ³³

Purpura Haemorrhagica ³³

Haemorrhagic Purpura ³³

Werlhof's Disease ¹¹

Werlhof Disease ³³

Aitp ⁵⁷

Characteristics:

Inheritance:

Autosomal dominant form ⁵⁷

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Immune diseases Blood diseases Bone diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

Coagulation defects, purpura and other haemorrhagic conditions

Purpura and other haemorrhagic conditions

Idiopathic thrombocytopenic purpura

ICD11: ³³

Diseases of the blood or blood-forming organs

Coagulation defects, purpura or other haemorrhagic or related conditions

Thrombocytopenia

Acquired thrombocytopenia

Immune thrombocytopenic purpura

External Ids:

Disease Ontology ¹¹ DOID:8924

OMIM® ⁵⁷ 188030

ICD9CM ³⁴ 287.31

MeSH ⁴³ D016553

NCIt ⁴⁹ C3446

SNOMED-CT ⁶⁸ 234490009

ICD10 ³¹ D69.3

MedGen ⁴⁰ C0398650

SNOMED-CT via HPO ⁶⁹ 248250000 302215000 415116008 more

EFO ¹⁶ EFO_0007160

ICD11 ³³ 364346400

UMLS ⁷¹ C0242584 C0272286 C0398650

Sources

Summaries for Thrombocytopenic Purpura, Autoimmune

GARD: ¹⁹ Idiopathic thrombocytopenic purpura (ITP) is a bleeding disorder characterized by too few platelets in the blood. This is because platelets are being destroyed by the immune system. Symptoms may include bruising, nosebleed or bleeding in the mouth, bleeding into the skin, and abnormally heavy menstruation. Rarely, ITP may become a chronic ailment in adults and reappear, even after remission.

MalaCards based summary: Thrombocytopenic Purpura, Autoimmune, also known as idiopathic thrombocytopenic purpura, is related to thrombotic thrombocytopenic purpura and thrombocytosis. An important gene associated with Thrombocytopenic Purpura, Autoimmune is SOCS1 (Suppressor Of Cytokine Signaling 1), and among its related pathways/superpathways are TGF-Beta Pathway and Response to elevated platelet cytosolic Ca2+. The drugs Rituximab and Amoxicillin have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and skin, and related phenotypes are thrombocytopenia and abnormal bleeding

OMIM®: ⁵⁷ Autoimmune thrombocytopenic purpura is characterized by a low platelet count, normal bone marrow, and the absence of other causes of thrombocytopenia. It is principally a disorder of increased platelet destruction mediated by autoantibodies to platelet-membrane antigens (George et al., 1994). (188030) (Updated 08-Dec-2022)

Disease Ontology: ¹¹ A primary thrombocytopenia that involves relatively few platelets in blood as a result of autoantibodies.

Wikipedia: ⁷⁵ Immune thrombocytopenic purpura (ITP), also known as idiopathic thrombocytopenic purpura or immune... more...

Sources

Related Diseases for Thrombocytopenic Purpura, Autoimmune

Diseases related to Thrombocytopenic Purpura, Autoimmune via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 986)

#	Related Disease	Score	Top Affiliating Genes
1	thrombotic thrombocytopenic purpura	31.3	SELP GP1BA F8
2	thrombocytosis	31.1	THPO SELP MPL IL11
3	viral infectious disease	31.1	IL18 IFNA2 ICOSLG CCR6
4	exanthem	31.0	IL18 ICOSLG CCR6
5	polycythemia	30.9	THPO MPL ITGB3
6	acquired thrombocytopenia	30.9	THPO MPL ITGB3 ITGA2B IL11 GP1BA
7	qualitative platelet defect	30.8	THPO SELP ITGA2B GP1BA
8	heparin-induced thrombocytopenia	30.7	ITGB3 ITGA2B
9	neutropenia	30.7	THPO MPL IL11 IFNA2
10	crohn's disease	30.7	S100A8 IL18 ICOSLG CCR6
11	hemorrhagic disease	30.7	THPO ITGA2B GP6 GP1BA F8
12	autoimmune polyendocrine syndrome	30.7	LRBA ICOSLG CCR6
13	agammaglobulinemia, x-linked	30.7	LRBA ICOSLG CCR6
14	myelofibrosis	30.7	THPO SELP MPL IFNA2
15	portal vein thrombosis	30.7	THPO MPL F8
16	infective endocarditis	30.7	ITGA2B GP1BA CCR6
17	anemia, autoimmune hemolytic	30.6	SOCS1 RHD LRBA ICOSLG CCR6
18	pulmonary embolism	30.6	GP6 GP1BA F8
19	celiac disease 1	30.6	IL18 ICOSLG HLA-DRB1 CCR6
20	aplastic anemia	30.6	THPO MPL IL11 GP1BA GATA3 CCR6
21	immunoglobulin alpha deficiency	30.6	LRBA ICOSLG CCR6
22	evans' syndrome	30.6	THPO MPL LRBA CCR6
23	splenic sequestration	30.6	THPO SELP MPL ITGA2B
24	thrombosis	30.5	SELP MPL ITGB3 ITGA2B GP6 GP1BA
25	hemolytic anemia	30.5	SOCS1 RHD LRBA IFNA2 CCR6
26	purpura	30.5	THPO SELP MPL ITGB3 ITGA2B HLA-DRB1
27	hematologic cancer	30.5	THPO MPL IL11 ICOSLG CCR6
28	hemoglobinuria	30.5	THPO SELP MPL HLA-DRB1
29	aspergillosis	30.5	IL18 HLA-DRB1 CCR6
30	colitis	30.5	SOCS1 IL18 IL11 ICOSLG HLA-DRB1 GATA3
31	thrombocythemia 1	30.4	THPO MPL
32	lymphadenitis	30.4	IL18 ICOSLG CCR6
33	herpes zoster	30.4	IFNA2 HLA-DRB1 CCR6
34	acquired von willebrand syndrome	30.4	GP6 GP1BA F8
35	myelodysplastic syndrome	30.4	THPO SOCS1 MPL IL11 IFNA2 ICOSLG
36	typhoid fever	30.4	RHD HLA-DRB1 CCR6
37	glanzmann thrombasthenia 1	30.3	SELP ITGB3 ITGA2B GP6 GP1BA F8
38	polyarteritis nodosa	30.3	SELP IFNA2 HLA-DRB1
39	proliferative glomerulonephritis	30.3	SELP ICOSLG CCR6
40	myocardial infarction	30.3	SELP ITGB3 ITGA2B IL18 GP6 GP1BA
41	myelitis	30.3	ITGB3 ITGA2B CCR6
42	bacterial sepsis	30.3	IL18 ICOSLG CCR6
43	coronary thrombosis	30.3	ITGB3 ITGA2B GP6 GP1BA
44	central nervous system vasculitis	30.3	ICOSLG HLA-DRB1 CCR6
45	autoimmune gastritis	30.3	S100A8 ICOSLG CCR6
46	severe covid-19	30.3	IL18 IFNA2 CCR6
47	langerhans cell histiocytosis	30.2	IL11 ICOSLG CCR6
48	childhood type dermatomyositis	30.2	ICOSLG HLA-DRB1 CCR6
49	fungal infectious disease	30.2	IL18 ICOSLG CCR6
50	vogt-koyanagi-harada disease	30.2	ICOSLG HLA-DRB1 CCR6

Graphical network of the top 20 diseases related to Thrombocytopenic Purpura, Autoimmune:

Sources

Symptoms & Phenotypes for Thrombocytopenic Purpura, Autoimmune

Human phenotypes related to Thrombocytopenic Purpura, Autoimmune:

³⁰

#	Description	HPO Source Accession
1	thrombocytopenia ³⁰	HP:0001873
2	abnormal bleeding ³⁰	HP:0001892
3	platelet antibody positive ³⁰	HP:0003454

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Heme:
thrombocytopenia
bleeding diathesis

Lab:
platelet antibody

Clinical features from OMIM®:

188030 (Updated 08-Dec-2022)

GenomeRNAi Phenotypes related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.2	CCR6 DNMT3B F8 GATA3 GP1BA GP6
2	no effect	GR00402-S-2	10.2	CCR6 DNMT3B F8 GATA3 GP1BA GP6
3	Decreased human papilloma virus 16 (HPV16) pseudovirus infection	GR00306-A	9.43	CCR6 DNMT3B GATA3 GP6 IL18 ITGA2B

MGI Mouse Phenotypes related to Thrombocytopenic Purpura, Autoimmune:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.06	CCR6 DNMT3B F8 GATA3 GP1BA GP6
2	immune system	MP:0005387	9.83	CCR6 DNMT3B F8 GATA3 GP6 ICOSLG
3	hematopoietic system	MP:0005397	9.55	CCR6 DNMT3B F8 GATA3 GP1BA GP6

Sources

Drugs & Therapeutics for Thrombocytopenic Purpura, Autoimmune

Drugs for Thrombocytopenic Purpura, Autoimmune (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Rituximab

Approved

Phase 4

174722-31-7

Amoxicillin

Approved, Vet_approved

Phase 4

26787-78-0

33613

Dexlansoprazole

Approved, Investigational

Phase 4

138530-94-6

9578005

Lansoprazole

Approved, Investigational

Phase 4

103577-45-3

3883

Clarithromycin

Approved

Phase 4

81103-11-9

84029

Azathioprine

Approved

Phase 4

446-86-6

2265

Alemtuzumab

Approved, Investigational

Phase 4

216503-57-0

Vincristine

Approved, Investigational

Phase 4

2068-78-2, 57-22-7

5978

Morphine

Approved, Investigational

Phase 4

57-27-2

5288826

Hydroxychloroquine

Approved

Phase 4

118-42-3

3652

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Glycyrrhizic acid

Approved, Experimental

Phase 4

1405-86-3

3495 14982

Peginterferon alfa-2b

Approved

Phase 4

215647-85-1, 99210-65-8

Cholecalciferol

Approved, Nutraceutical, Vet_approved

Phase 4

67-97-0, 1406-16-2

5280795 10883523

Calcitriol

Approved, Nutraceutical

Phase 4

32222-06-3

5280453

3,4-Dihydroxycinnamic Acid

Experimental, Investigational

Phase 4

331-39-5, 501-16-6

689043

Enoxolone

Investigational

Phase 4

471-53-4

3230 18526330 10114

Antineoplastic Agents, Immunological

Phase 4

Vitamins

Phase 4

Calciferol

Phase 4

Trace Elements

Phase 4

Vasoconstrictor Agents

Phase 4

Micronutrients

Phase 4

Anti-Ulcer Agents

Phase 4

Antacids

Phase 4

Cytochrome P-450 Enzyme Inhibitors

Phase 4

Cytochrome P-450 CYP3A Inhibitors

Phase 4

Antiprotozoal Agents

Phase 4

Antiparasitic Agents

Phase 4

Neuroprotective Agents

Phase 4

Antimitotic Agents

Phase 4

Tubulin Modulators

Phase 4

Antimalarials

Phase 4

Immunologic Factors

Phase 4

Anti-Infective Agents

Phase 4

Autoantibodies

Phase 4

Antiviral Agents

Phase 4

Interferon alpha-2

Phase 4

interferons

Phase 4

Interferon-alpha

Phase 4

Metronidazole

Approved

Phase 3

443-48-1, 69198-10-3

4173

Pantoprazole

Approved

Phase 3

102625-70-7, 138786-67-1

4679

Hydrocortisone succinate

Approved

Phase 3

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 3

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 3

50-23-7

3640 5754

Levoleucovorin

Approved, Experimental, Investigational

Phase 3

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Dapsone

Approved, Investigational

Phase 3

80-08-0

2955

Oseltamivir

Approved

Phase 3

204255-11-8, 196618-13-0

65028

Selenium

Approved, Investigational, Vet_approved

Phase 2, Phase 3

7783-07-5, 7782-49-2

533

Interventional clinical trials:

(show top 50) (show all 364)

#	Name	Status	NCT ID	Phase	Drugs
1	Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura	Unknown status	NCT03172676	Phase 4	Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
2	Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia in Pediatrics	Unknown status	NCT04102033	Phase 4	Eltrombopag
3	Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial	Unknown status	NCT03771378	Phase 4	rhTPO;eltrombopag
4	A Multicenter Randomized Open-label Clinical Trial of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP	Unknown status	NCT04094805	Phase 4	Rocaltrol;Dexamethasone
5	A Multicenter, Randomized, Open-label Study To Compare The Efficacy And Safety Of Eltrombopag Combining Rituximab With Eltrombopag In Adult ITP Patients	Unknown status	NCT04518475	Phase 4	eltrombopag combining rituximab;eltrombopag
6	Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura	Completed	NCT00467571	Phase 4	lansoprazole, clarithromycin, amoxycillin
7	A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)	Completed	NCT01098487	Phase 4	Eltrombopag olamine
8	A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP)	Completed	NCT00907478	Phase 4
9	Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag.	Completed	NCT00888901	Phase 4	eltrombopag;corticosteroids (Aprednislon)
10	An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis	Completed	NCT01390649	Phase 4
11	Collection of Blood Samples From Patients With Relapsing Forms of Multiple Sclerosis (RMS) Who Have Developed Immune Thrombocytopenic Purpura (ITP) After LEMTRADA® Treatment	Completed	NCT03784898	Phase 4
12	The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia	Completed	NCT03258866	Phase 4	Rituximab
13	High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial	Completed	NCT01356511	Phase 4	Prednisone;Dexamethasone
14	A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP)	Completed	NCT02556814	Phase 4	Caffeic acid tablets;Dexamethasone;placebo
15	Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)	Completed	NCT04089267	Phase 4	TPO
16	Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim	Completed	NCT02760251	Phase 4	romiplostim
17	Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia	Completed	NCT03229746	Phase 4	Hydroxychloroquine;vincristine;azathioprine
18	Short-course High-dose Prednisone and Dexamethasone in Children With Immune A Multicenter, Randomized Controlled Study of Thrombocytopenia	Recruiting	NCT05522465	Phase 4	Prednisone;Dexamethasone
19	Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)	Recruiting	NCT03866798	Phase 4
20	Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim	Recruiting	NCT04638829	Phase 4	Avatrombopag Oral Tablet
21	A Multicenter, Randomized Controlled Study of Two Regimens of Intravenous Immune Globulin in the Treatment of Newly Diagnosed Immune Thrombocytopenia in Children	Recruiting	NCT05520892	Phase 4	intravenous immunoglobulin
22	A Single-center Prospective Randomized Study of Glycyrrhetinic Acid Combined With Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP)	Recruiting	NCT03998982	Phase 4	Glycyrrhetinic Acid;Dexamethasone
23	Efficacy and Safety of Eltrombopag Combined With Low-dose Rituximab in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Fail to First-line Treatment: a Prospective, Open-label, Nonrandomized, Multicenter Clinical Trial	Recruiting	NCT04915482	Phase 4	Combined use of eltrombopag with low-dose rituximab;The best available therapy
24	A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency)	Recruiting	NCT03201848	Phase 4	Placebo;Huaiqihuang Granule
25	Efficacy and Safety of Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Fail to Eltrombopag or Herombopag Treatment: a Single-center, Prospective, One-arm Clinical Trial	Recruiting	NCT04993885	Phase 4	Avatrombopag
26	A Prospective, Single-center Clinical Trial of Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in the Treatment of Childhood and Adolescent Essential Thrombocythemia	Recruiting	NCT04226950	Phase 4	Recombinant Interferon Alpha;Pegylated interferon alfa-2b
27	A Prospective, Multicenter, Randomized Controlled Clinical Trial of Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in the Treatment of Adult Essential Thrombocythemia	Recruiting	NCT05395507	Phase 4	Recombinant Interferon Alpha;Pegylated interferon alfa-2b
28	Comparing the Efficacy and Safety of Optimized rhTPO Treatment Versus Eltrombopag Treatment in Previously Treated Primary Immune Thrombocytopenia Patients: A Multicenter Randomized Open-label Trial	Not yet recruiting	NCT05583838	Phase 4	rhTPO;Eltrombopag
29	Efficacy and Safety of TPO Receptor Agonists as First-line Drugs in the Treatment of Newly Diagnosed Elderly ITP Patients in China-an Open Label Study	Not yet recruiting	NCT05311930	Phase 4	2.5mg/d Hetrombopag
30	Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP): a Prospective, Randomized Controlled Trial	Withdrawn	NCT02642380	Phase 4	Dexamethasone (4 cycles);Dexamethasone (1 cycle)
31	A Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune Thrombocytopenia	Unknown status	NCT01805648	Phase 3	rhTPO
32	Efficacy of Helicobacter Pylori Eradication for the Treatment of Chronic or Persistent Immune Thrombocytopenic Purpura Patients With Moderate Thrombocytopenia: Multicenter Prospective Randomized Phase 3 Study	Unknown status	NCT03177629	Phase 3	treatment : H. pylori eradication
33	Association of FC Gamma RIIIA Polymorphism and Thrombopoietin (THPO) Expression With Response to TPO Agonists in Refractory ITP and the Impact of Therapy on B and T Cells Subsets in the Patients With Mutated Genotypes	Unknown status	NCT02877212	Phase 3	Eltrombopag
34	A Multicenter Prospective Randomized Study of Dexamethasone Combined With Decitabine Versus Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP)	Unknown status	NCT03252457	Phase 3	Decitabine;Dexamethasone
35	A Multicenter Prospective Randomized Study of Rituximab Combined With Bortezomib Versus Rituximab in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP)	Unknown status	NCT03443570	Phase 3	Rituximab;Bortezomib
36	Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia	Unknown status	NCT02627417	Phase 3	Dapsone (Disulone®);Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";Prednisone (Cortancyl®)
37	Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP)in Pregnancy: a Single-center Clinical Trial	Unknown status	NCT02270801	Phase 3	rhTPO
38	Thrombocytopenia in Gestational Period	Unknown status	NCT02751593	Phase 2, Phase 3	Dexamethasone
39	Proof of Concept; A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia	Unknown status	NCT03520049	Phase 3	Oseltamivir;Placebo
40	Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy	Unknown status	NCT01763658	Phase 2, Phase 3	Antox tablets(Mepaco)
41	A Multicenter Clinical Study of Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia	Unknown status	NCT03492515	Phase 3	recombinant human thrombopoietin;Platelet Concentrate
42	A Multicenter Randomized Study of Dexamethasone Combined With Rituximab, Cyclosporin and Intravenous Immunoglobulin in the Management of Newly Diagnosed ITP Patients	Unknown status	NCT02834468	Phase 3	DEX Combined With RTX, CSA and IVIG
43	A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)	Completed	NCT01444417	Phase 3	Romiplostim;Placebo
44	Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)-An Extension Study of Eltrombopag in Subjects, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study TRA108109 (NCT00540423)-<Phase III Study>	Completed	NCT00828750	Phase 3	Eltrombopag oral tablets
45	A Randomized, Controlled, Open-label Study Evaluating the Efficacy and Tolerability of AMG 531 Versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects With Immune (Idiopathic) Thrombocytopenic Purpura	Completed	NCT00415532	Phase 3	Medical Standard of Care for ITP
46	A Randomized, Open-label Study of First-line Treatment With Dexamethasone or Dexamethasone Plus MabThera on Sustained Treatment Response in Adult Patients With Idiopathic Thrombocytopenic Purpura	Completed	NCT00770562	Phase 3	rituximab;Dexamethasone
47	Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP) -A Multicenter Study in Subjects With Chronic ITP Receiving a Double-Blind, Placebo-Controlled, Short-Term Treatment Followed by an Open-Label, Uncontrolled, Long-Term Treatment- <Phase II/III Study>	Completed	NCT00540423	Phase 3	SB-497115-GR 12.5mg;SB-497115-GR 25mg;SB-497115-GR 12.5mg matching placebo;SB-497115-GR 50 mg
48	A Randomized Controlled Multicentre Trial of High Dose Dexamethasone Versus Conventional Dose Prednisolone for Adults With Untreated Idiopathic Thrombocytopenic Purpura	Completed	NCT00451594	Phase 3	Dexamethasone;Prednisolone
49	A Phase III, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of GAMMAPLEX® in Chronic Idiopathic Thrombocytopenic Purpura	Completed	NCT00504075	Phase 3
50	Clinical Study to Evaluate the Efficacy and Safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in Adults	Completed	NCT00426270	Phase 3	Octagam 10%

Search NIH Clinical Center for Thrombocytopenic Purpura, Autoimmune

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Azathioprine

Cyclophosphamide

Immunoglobulins, Intravenous

Intramuscular immunoglobulin

Rho(D) Immune Globulin, human

Venoglobulin-I

Vinblastine

Vinblastine Sulfate

Cochrane evidence based reviews: purpura, thrombocytopenic, idiopathic

Sources

Genetic Tests for Thrombocytopenic Purpura, Autoimmune

Genetic tests related to Thrombocytopenic Purpura, Autoimmune:

#	Genetic test	Affiliating Genes
1	Autoimmune Thrombocytopenic Purpura ²⁸

Sources

Anatomical Context for Thrombocytopenic Purpura, Autoimmune

Organs/tissues related to Thrombocytopenic Purpura, Autoimmune:

MalaCards : Bone Marrow, Bone, Skin, T Cells, Spleen, B Cells, Liver

Sources

Publications for Thrombocytopenic Purpura, Autoimmune

Articles related to Thrombocytopenic Purpura, Autoimmune:

(show top 50) (show all 7936)

#	Title	Authors	PMID	Year
1	Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients. ⁶² ⁵⁷	Asahi A...Kuwana M	18654664	2008
2	Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. ⁶² ⁵⁷	Breunis WB...Kuijpers TW	17827395	2008
3	Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. ⁶² ⁵⁷	Fujimura K...Ikeda Y	15765787	2005
4	Historical aspects and present knowledge of idiopathic thrombocytopenic purpura. ⁶² ⁵⁷	Imbach P...Signer E	12472565	2002
5	Immune thrombocytopenic purpura. ⁶² ⁵⁷	Cines DB...Blanchette VS	11919310	2002
6	Chronic idiopathic thrombocytopenic purpura. ⁶² ⁵⁷	George JN...Raskob GE	7935660	1994
7	Idiopathic thrombocytopenic purpura in two elderly siblings. ⁶² ⁵⁷	Bogart L...Wittels EG	4074042	1985
8	Autoimmune thrombocytopenic purpura. ⁶² ⁵⁷	Karpatkin S	2413550	1985
9	Chronic immune thrombocytopenic purpura in monozygotic twins: genetic factors predisposing to ITP. ⁶² ⁵⁷	Laster AJ...Bias WB	6890627	1982
10	Specificity of autoantibodies in autoimmune thrombocytopenia. ⁶² ⁵⁷	van Leeuwen EF...von dem Borne AE	7032627	1982
11	Hereditary autoimmune thrombocytopenic purpura: an immunologic and genetic study. ⁶² ⁵⁷	Karpatkin S...Winchester R	7195175	1981
12	Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. ⁵⁷	Gasbarrini A...Gasbarrini G	9742983	1998
13	Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. ⁵⁷	HARRINGTON WJ...MOORE CV	14850832	1951
14	Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults. ⁵³ ⁶²	Lam MS	19525300	2010
15	[Expression of T-bet and GATA3 in children with acute idiopathic thrombocytopenic purpura]. ⁵³ ⁶²	Ren SM...Li WC	20113630	2010
16	Thyroid-associated autoimmune coagulation disorders. ⁵³ ⁶²	Franchini M...Vescovi PP	19277469	2010
17	High-dose dexamethasone regulates interleukin-18 and interleukin-18 binding protein in idiopathic thrombocytopenic purpura. ⁵³ ⁶²	Shan NN...Hou M	19797730	2009
18	New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. ⁵³ ⁶²	Arnold DM...Kelton JG	19426124	2009
19	Interleukin 18 and interleukin 18 binding protein in patients with idiopathic thrombocytopenic purpura. ⁵³ ⁶²	Shan NN...Hou M	19077159	2009
20	Romiplostim. ⁵³ ⁶²	Frampton JE...Lyseng-Williamson KA	19275274	2009
21	Single nucleotide polymorphism in DNMT3B promoter and the risk for idiopathic thrombocytopenic purpura in Chinese population. ⁵³ ⁶²	Chen Z...Yang R	18437543	2008
22	[Expression of co-stimulatory molecules and role of interleukin 18 in peripheral lymphocytes of patients with idiopathic thrombocytopenic purpura]. ⁵³ ⁶²	Pan JL...He X	17605869	2007
23	Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura. ⁵³ ⁶²	Sukati H...Barker RN	17272505	2007
24	Immune response to CagA protein is associated with improved platelet count after Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura. ⁵³ ⁶²	Kodama M...Chayama K	17241299	2007
25	Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover. ⁵³ ⁶²	Yamazaki R...Okamoto S	16915226	2006
26	Novel heterozygous missense mutation in the second leucine rich repeat of GPIbalpha affects GPIb/IX/V expression and results in macrothrombocytopenia in a patient initially misdiagnosed with idiopathic thrombocytopenic purpura. ⁵³ ⁶²	Kunishima S...Saito H	16519708	2006
27	[Curative effect of interleukin 11 on chronic idiopathic thrombocytopenic purpura]. ⁵³ ⁶²	Zhang QR...Cao RN	16584619	2006
28	Multiple cycles of recombinant human thrombopoietin therapy in a patient with chronic refractory idiopathic thrombocytopenic purpura. ⁵³ ⁶²	Hua B...Zhao Y	15870550	2005
29	Increased glycocalicin index and normal thrombopoietin levels in patients with idiopathic thrombocytopenic purpura with a decreased rate of platelet production. ⁵³ ⁶²	Houwerzijl EJ...de Wolf JT	15921398	2005
30	Danazol, idiopathic thrombocytopenic purpura, and thrombopoietin. ⁵³ ⁶²	Rice L	15629743	2004
31	Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. ⁵³ ⁶²	Boylan B...Newman PJ	15150079	2004
32	[A multi-center clinical trial of recombinant human thrombopoietin in chronic refractory idiopathic thrombocytopenic purpura]. ⁵³ ⁶²	Zhao YQ...Shan YD	15355668	2004
33	Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. ⁵³ ⁶²	Takahashi T...Tanizawa Y	14675413	2004
34	[Interleukin-18 and its related cytokines in plasma of patients with idiopathic thrombocytopenic purpura]. ⁵³ ⁶²	Zhang LQ...Zhao HR	14706156	2003
35	Soluble P-selectin, interleukin 6, and thrombopoietin levels in children with acute and chronic idiopathic thrombocytopenic purpura and their relationship with mega-dose methylprednisolone therapy: a pilot study. ⁵³ ⁶²	Olcay L...Yetgin S	12468916	2002
36	Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. ⁵³ ⁶²	Kuter DJ...Begley CG	12411315	2002
37	[Study on the relations between HLA-DRB1 alleles and idiopathic thrombocytopenic purpura in children]. ⁵³ ⁶²	Wang H...Hou H	12170464	2002
38	Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia. ⁵³ ⁶²	Kuwana M...Ikeda Y	12209520	2002
39	Plasma thrombopoietin levels in patients with aplastic anemia and idiopathic thrombocytopenic purpura. ⁵³ ⁶²	Gu J...Chen X	12150725	2002
40	The potential role of thrombopoietin in idiopathic thrombocytopenic purpura. ⁵³ ⁶²	von dem Borne A...de Haas M	11913997	2002
41	[The effects of thrombopoietin and interleukin-11 on bone marrow megakaryocytic progenitors in patients with chronic idiopathic thrombocytopenic purpura in vitro]. ⁵³ ⁶²	Liao X...Meng W	12528552	2001
42	[The relativity study of thrombopoietin and chronic idiopathic thrombocytopenic purpura]. ⁵³ ⁶²	Liao X...Deng C	11758228	2001
43	Colony-forming unit-megakaryocyte (CFR-meg) numbers and serum thrombopoietin concentrations in thrombocytopenic disorders: an inverse correlation in myelodysplastic syndromes. ⁵³ ⁶²	Wang W...Tomonaga M	11021750	2000
44	[Clinical study on interferon treatment of chronic idiopathic thrombocytopenic purpura]. ⁵³ ⁶²	Deng C...Li S	12545843	2000
45	[The sensitivity, specificity and predictive value of PAIgG, reticulated platelets, thrombopoietin levels, and platelet size for the differential diagnosis of thrombocytopenia]. ⁵³ ⁶²	Kurata Y...Tomiyama Y	10624125	1999
46	Serum thrombopoietin levels in thrombocytopenic and non-thrombocytopenic patients with human immunodeficiency virus (HIV-1) infection. ⁵³ ⁶²	Espanol I...Pujol-Moix N	10530413	1999
47	Serum levels of thrombopoietin, IL-11, and IL-6 in pediatric thrombocytopenias. ⁵³ ⁶²	Cremer M...Ballmaier M	10525827	1999
48	Usefulness of thrombopoietin in the diagnosis of peripheral thrombocytopenias. ⁵³ ⁶²	Espanol I...Pujol-Moix N	10406902	1999
49	Systemic causes of excessive uterine bleeding. ⁵³ ⁶²	Lusher JM	10513767	1999
50	Thrombopoietin, interleukin-6, and P-selectin at diagnosis and during post-steroid recovery period of patients with autoimmune thrombocytopenic purpura. ⁵³ ⁶²	Haznedaroglu IC...Dundar SV	9829848	1998

Sources

Genes for Thrombocytopenic Purpura, Autoimmune

Genes related to Thrombocytopenic Purpura, Autoimmune (0 elite genes):

(show all 29)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	SOCS1	Suppressor Of Cytokine Signaling 1	Protein Coding	28.65	Likely pathogenic ⁵ DISEASES inferred ¹⁴
2	THPO	Thrombopoietin	Protein Coding	17.96	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9690802 11913997 9829848 (more) 11758228 9639498 12528552 15355668 15870550 9351524 9633881 12150725 9657432 19525300 16915226 12411315 10624125 8865522 8698134 8639762 12468916 10406902 19426124 11021750 8888496 15921398 10530413 9369414 15629743 10525827 19275274
3	MPL	MPL Proto-Oncogene, Thrombopoietin Receptor	Protein Coding	16.92	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9633881 12209520 19275274 (more) 8865522
4	LRBA	LPS Responsive Beige-Like Anchor Protein	Protein Coding	14.05	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
5	GP1BA	Glycoprotein Ib Platelet Subunit Alpha	Protein Coding	12.74	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16519708 7579346 15921398
6	ITGB3	Integrin Subunit Beta 3	Protein Coding	11.73	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17272505
7	DNMT3B	DNA Methyltransferase 3 Beta	Protein Coding	10.21	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18437543
8	SELP	Selectin P	Protein Coding	10.13	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7507587 9829848 12468916
9	IFNA2	Interferon Alpha 2	Protein Coding	10.13	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8372806 8571936 7605454 (more) 8492419 1433917 7977252 1581224 12545843 8329555
10	IL11	Interleukin 11	Protein Coding	9.5	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16584619 12528552
11	GATA3	GATA Binding Protein 3	Protein Coding	9.17	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	20113630
12	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	8.56	DISEASES inferred ¹⁴ ¹⁴
13	GP6	Glycoprotein VI Platelet	Protein Coding	8.55	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15150079
14	F8	Coagulation Factor VIII	Protein Coding	8.09	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10513767 19277469
15	IL18	Interleukin 18	Protein Coding	7.92	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14706156 17605869 19077159 (more) 19797730
16	ITGA2B	Integrin Subunit Alpha 2b	Protein Coding	7.86	DISEASES inferred ¹⁴
17	RHD	Rh Blood Group D Antigen	Protein Coding	7.84	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1313096
18	S100A8	S100 Calcium Binding Protein A8	Protein Coding	7.8	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17241299 14675413
19	HLA-DRB1	Major Histocompatibility Complex, Class II, DR Beta 1	Protein Coding	7.55	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12170464
20	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	7.25	DISEASES inferred ¹⁴ ¹⁴
21	CD4	CD4 Molecule	Protein Coding	6.85	DISEASES inferred ¹⁴
22	ADAMTS13	ADAM Metallopeptidase With Thrombospondin Type 1 Motif 13	Protein Coding	6.78	DISEASES inferred ¹⁴
23	F3	Coagulation Factor III, Tissue Factor	Protein Coding	6.59	DISEASES inferred ¹⁴
24	PF4	Platelet Factor 4	Protein Coding	6.5	DISEASES inferred ¹⁴
25	CD8A	CD8a Molecule	Protein Coding	6.46	DISEASES inferred ¹⁴
26	FCGR2B	Fc Gamma Receptor IIb	Protein Coding	6.45	DISEASES inferred ¹⁴
27	FCGR2A	Fc Gamma Receptor IIa	Protein Coding	6.4	DISEASES inferred ¹⁴
28	F2	Coagulation Factor II, Thrombin	Protein Coding	6.4	DISEASES inferred ¹⁴
29	CD52	CD52 Molecule	Protein Coding	6.37	DISEASES inferred ¹⁴

Sources

Variations for Thrombocytopenic Purpura, Autoimmune

ClinVar genetic disease variations for Thrombocytopenic Purpura, Autoimmune:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	SOCS1	NM_003745.2(SOCS1):c.368C>G (p.Pro123Arg)	SNV	Likely Pathogenic	977212	rs1244284678	GRCh37: 16:11348968-11348968 GRCh38: 16:11255111-11255111
2	SOCS1	NM_003745.2(SOCS1):c.476_480dup (p.Met161fs)	MICROSAT	Likely Pathogenic	977214	rs1470306246	GRCh37: 16:11348855-11348856 GRCh38: 16:11254998-11254999
3	SOCS1	NM_003745.2(SOCS1):c.24del (p.Ala9fs)	DEL	Likely Pathogenic	977213	rs2069587477	GRCh37: 16:11349312-11349312 GRCh38: 16:11255455-11255455

Copy number variations for Thrombocytopenic Purpura, Autoimmune from CNVD:

⁶

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	21699	1	160500000	165500000	Copy number	FCGR2C	Idiopathic thrombocytopenic purpura
2	121460	18	43500000	48200000	Copy number	SMAD4	Idiopathic thrombocytopenic purpura
3	46119	10	77700000	82000000	Copy number	BMPR1A	Idiopathic thrombocytopenic purpura

Sources

Expression for Thrombocytopenic Purpura, Autoimmune

Search GEO for disease gene expression data for Thrombocytopenic Purpura, Autoimmune.

Sources

Pathways for Thrombocytopenic Purpura, Autoimmune

Pathways related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.24	THPO SOCS1 MPL ITGB3 ITGA2B IL18
2	Response to elevated platelet cytosolic Ca2+ ⁶⁶ Show member pathways Disinhibition of SNARE formation ⁶⁶ Hemostasis ⁶⁶ Platelet activation, signaling and aggregation ⁶⁶ Platelet degranulation ⁶⁶	12.72	THPO SELP MPL ITGB3 ITGA2B IFNA2
3	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.69	SOCS1 IL18 GATA3
4	Integrin signaling ⁶⁶ Show member pathways GRB2:SOS provides linkage to MAPK signaling for Integrins ⁶⁶ p130Cas linkage to MAPK signaling for integrins ⁶⁶ Platelet Aggregation (Plug Formation) ⁶⁶	11.54	THPO MPL ITGB3 ITGA2B GP1BA
5	Innate Lymphoid Cells Differentiation ⁶⁵	11.51	IL18 GATA3 CCR6
6	IL4-mediated signaling events ⁶¹	11.32	SOCS1 SELP ITGB3
7	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.23	THPO MPL ITGB3 ITGA2B IL11 IFNA2
8	Platelet Aggregation Inhibitor Pathway, Pharmacodynamics ⁶⁰	11.21	ITGB3 ITGA2B GP6
9	Heparin-induced Thrombocytopenia Pathway, Adverse Drug Reaction ⁶⁰	11	HLA-DRB1 ITGA2B ITGB3
10	G-protein signaling_Rap2B regulation pathway ²²	10.76	THPO ITGB3 ITGA2B IL18 IL11

Sources

GO Terms for Thrombocytopenic Purpura, Autoimmune

Cellular components related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	plasma membrane	GO:0005886	10.28	SELP RHD ITGB3 HLA-DRB1 GP6 GP1BA
2	plasma membrane	GO:0005887	10.28	SELP RHD ITGB3 HLA-DRB1 GP6 GP1BA
3	cell surface	GO:0009986	10	CCR6 GP1BA GP6 HLA-DRB1 ITGA2B ITGB3
4	external side of plasma membrane	GO:0009897	9.5	SELP MPL ITGB3 ITGA2B ICOSLG HLA-DRB1
5	platelet alpha granule membrane	GO:0031092	9.43	SELP ITGB3 ITGA2B

Biological processes related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	regulation of cytokine production	GO:0001817	9.91	SOCS1 ICOSLG GATA3
2	platelet aggregation	GO:0070527	9.88	MPL ITGB3 GP1BA
3	blood coagulation, intrinsic pathway	GO:0007597	9.76	GP1BA F8
4	thrombopoietin-mediated signaling pathway	GO:0038163	9.67	MPL THPO
5	lymphocyte migration	GO:0072676	9.62	CCR6 GATA3
6	regulation of T-helper cell differentiation	GO:0045622	9.56	HLA-DRB1 GATA3
7	blood coagulation	GO:0007596	9.5	ITGB3 GP6 GP1BA F8
8	hemostasis	GO:0007599	9.33	GP6 GP1BA F8
9	humoral immune response	GO:0006959	9.23	IFNA2 HLA-DRB1 GATA3 CCR6